Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015)
https://doi.org/10.14341/DM201515-23
Abstract
The current update of the consensus algorithm of initiation and intensification of the antihyperglicemic therapy in treatment of the patients with type 2 diabetes mellitus (2015) is based on the preliminary document issued by the Russian Association of the Endocrinologists in 2011.
The update was needed due to new data on the safety of the traditional therapeutic options, availability of the new class of the antidiabetic medications, and necessity to add chapter about initiation and intensification of the insulin therapy.
The patient-centered approach remains the absolute priority at any stage of diabetes care as it ensures the efficacy and safety of antihyperglycaemic treatment.
The update was needed due to new data on the safety of the traditional therapeutic options, availability of the new class of the antidiabetic medications, and necessity to add chapter about initiation and intensification of the insulin therapy.
The patient-centered approach remains the absolute priority at any stage of diabetes care as it ensures the efficacy and safety of antihyperglycaemic treatment.
About the Authors
Ivan Ivanovich Dedov
Endocrinology Research Centre, Moscow
Russian Federation
MD, PhD, Professor, Academician of Russian Academy of Sciences, Director of Endocrinology Research Centre
Russian Federation
MD, PhD, Professor, Academician of Russian Academy of Sciences, Director of Endocrinology Research Centre
Marina Vladimirovna Shestakova
Endocrinology Research Centre, Moscow; I.M.Sechenov First Moscow State Medical University, Moscow
Russian Federation
MD, PhD, Professor, corresponding member of Russian Academy of Sciences, Head of the Diabetes Institute of Endocrinology research centre, Chief of the Pediatric endocrinology and diabetology chair of Sechenov University
Russian Federation
MD, PhD, Professor, corresponding member of Russian Academy of Sciences, Head of the Diabetes Institute of Endocrinology research centre, Chief of the Pediatric endocrinology and diabetology chair of Sechenov University
Alexander Sergeevich Ametov
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
MD, PhD, Professor, Head of the endocrinology department
Russian Federation
MD, PhD, Professor, Head of the endocrinology department
Mikhail Borisovich Antsiferov
Moscow Department of Health, Moscow
Russian Federation
ME, PhD, Professor, Cheif endocrinologist of Moscow-City
Russian Federation
ME, PhD, Professor, Cheif endocrinologist of Moscow-City
Gagik Radikovich Galstyan
Endocrinology Research Centre, Moscow; I.M.Sechenov First Moscow State Medical University, Moscow
Russian Federation
MD, PhD, Professor, Head of the Diabetic foot department of Endocrinology research centre
Russian Federation
MD, PhD, Professor, Head of the Diabetic foot department of Endocrinology research centre
Alexander Yur'evich Mayorov
Endocrinology Research Centre, Moscow; I.M.Sechenov First Moscow State Medical University, Moscow
Russian Federation
MD, PhD, Head of the Programme education and therapy department of Endocrinology research centre
Russian Federation
MD, PhD, Head of the Programme education and therapy department of Endocrinology research centre
Ashot Musaelovich Mkrtumyan
State University of Medicine and Dentistry named after A.I.Evdokimov, Moscow
Russian Federation
MD, PhD, Professor, Chief of the Endocrinology Chair
Russian Federation
MD, PhD, Professor, Chief of the Endocrinology Chair
Nina Alexandrovna Petunina
I.M.Sechenov First Moscow State Medical University, Moscow
Russian Federation
MD, PhD, Professor, Head of the Endocrinology department of postgraduate faculty
Russian Federation
MD, PhD, Professor, Head of the Endocrinology department of postgraduate faculty
Olga Yur'evna Sukhareva
Endocrinology Research Centre, Moscow
Russian Federation
MD, PhD, Cheif researcher of the Diabetes nephropathy department of Endocrinology research centre
Russian Federation
MD, PhD, Cheif researcher of the Diabetes nephropathy department of Endocrinology research centre
References
1. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т.18. – №1S. – С. 1–112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1–112.] doi: 10.14341/DM20151S1-112
2. Дедов И.И., Шестакова М.В., Аметов А.С., и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. // Сахарный диабет. – 2011. – №4. – С. 6–17. [Dedov II, Shestakova MV, Ametov AS, et al. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;14(4):6–17.] doi: 10.14341/2072-0351-5810
3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine practice. 2009;15(6):540–559. doi: 10.4158/EP.15.6.540
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–442. doi: 10.1007/s00125-014-3460-0
5. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England journal of medicine. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England journal of medicine. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431
7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
8. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987
9. Дедов И.И., Шестакова М.В., Александров А.А., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (6-й выпуск). // Сахарный диабет. – 2013. – №1(приложение 1). – С. 1–120. [Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1–120.] doi: 10.14341/DM20131S1-121
10. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes care. 2011;34(6):1431–1437. doi: 10.2337/dc10-2361
11. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52(3):741–750.
12. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–1704. doi: 10.2337/db05-1602
13. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684
14. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889
15. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine reviews. 2012;33(2):187–215. doi: 10.1210/er.2011-1052
16. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessent. The New England journal of medicine. 2014;370(9):794–797. doi: 10.1056/NEJMp1314078
17. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. British journal of pharmacology. 2003;140(1):123–132. doi: 10.1038/sj.bjp.0705397
18. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–2276. doi: 10.2337/diabetes.48.12.2270
19. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes care. 2007;30(2):389–394. doi: 10.2337/dc06-1789
20. U.S. Food and Drug Administration. FDA News Release (25-nov-2013): FDA requires removal of certain restrictions on the diabetes drug Avandia. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
21. Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493–504. doi: 10.1007/s00125-014-3456-9
22. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy. 2014;8:1335–1380. doi: 10.2147/DDDT.S50773
23. American Diabetes Asosiation. Approaches to Glycemic Treatment. Diabetes care. 2015;38(Supplement 1):S41–S48. doi: 10.2337/dc15-S010
24. Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes care. 2014;37(7):1815–1823. doi: 10.2337/dc13-3055
25. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathwys and review of ongoing outcome trials. Diabetes & vascular disease research. 2015;12(2):90–100. doi: 10.1177/1479164114559852
26. Дедов И.И., Шестакова М.В., Абусуев С.А., и др. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации). // Сахарный диабет. – 2010. – №5. – С. 9–16. [Dedov II, Shestakova MV, Abusuev SA, Valeeva FV, Verbovoy AF, Galstyan GR, et al. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). Diabetes mellitus. 2010;13(5):9–16.] doi: 10.14341/2072-0351-6049
Supplementary files
|
|
1. рис.1 | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(447KB)
|
Indexing metadata ▾ | |
Review
For citations:
Dedov I.I., Shestakova M.V., Ametov A.S., Antsiferov M.B., Galstyan G.R., Mayorov A.Yu., Mkrtumyan A.M., Petunina N.A., Sukhareva O.Yu. Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015). Diabetes mellitus. 2015;18(1):5-23. (In Russ.) https://doi.org/10.14341/DM201515-23
Views:
953
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
